Erlotinib may confer an economic advantage for payers over docetaxel and pemetrexed for second-line treatment of lung cancer because of lower costs.
Stephen Lash, PharmD
Advertisement
Articles by Stephen Lash, PharmD
Advertisement
Latest Updated Articles
- Costs Associated With Second-Line Therapies for Lung Cancer
February 1st 2011
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
3
Beyond Weight Loss: Exploring the Renal and Anti-Inflammatory Benefits of High-Dose Semaglutide
4
ADA 2026: The 2026 ADA Standards – A Pharmacist's Guide to Cardiorenal Risk Reduction
5